Selection of metastasis competent subclones in the tumour interior: TRACERx renal

Abstract

While the genetic evolutionary features of solid tumour growth are becoming increasingly described, the spatial and physical nature of subclonal growth remains unclear. Here we utilise 102 macroscopic whole tumour images from clear cell renal cell carcinoma (ccRCC) patients, with matched genetic and phenotypic data from 756 biopsies. Utilising a digital image processing pipeline the boundaries between tumour and normal tissue were marked by a renal pathologist, and positions of boundary line and biopsy regions were extracted to X- and Y-coordinates. The coordinates were then integrated with genomic data to map exact spatial subclone locations, revealing how genetically distinct subclones grow and evolve spatially. A phenotype of advanced and more aggressive subclonal growth was present in the tumour centre, characterised by an elevated burden of somatic copy number alterations, higher necrosis, proliferation rate and Fuhrman grade. Moreover, metastasising subclones were found to preferentially originate from the tumour centre. Collectively these observations suggest a model of accelerated evolution in the tumour interior, with harsh hypoxic environmental conditions leading to heightened cellular turnover and greater opportunity for driver SCNAs to arise and expand due to selective advantage. Tumour subclone growth was found to be predominantly spatially contiguous in nature, with subclone dispersal a rare event found in two cases, which notably was associated with metastasis. In terms of genetic events, the largest subclones spatially were dominated by driver somatic copy number alterations, suggesting a large selective advantage can be conferred to subclones upon acquisition of these alterations. In conclusion, spatial dynamics is strongly associated with genomic alterations and plays an important role in tumour evolution.

Patient-derived triple negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics

“…We hypothesize that in PDOs with these expression signatures, the cells that exhibit a MYC-low/hypoxia-high profile are the likely candidates for chemotherapy escape (Fig 7F). Additionally, fate mapping and other studies have shown that tumor cells exposed to hypoxia have a higher tendency to result in metastasis (62, 63). It remains to be tested to what extent these MYC-low/hypoxia-high cells contribute towards metastasis and/or chemotherapy resistance, and these patient-derived organoids will be an invaluable tool to answer these questions.…”

Spatial omics: Navigating to the golden era of cancer research

“…Evolution is the driving force behind cancer cell resistance or metastasis 122,123 . Previous research largely relied on multi‐region sample collection, 124 where directly modelling the spatial evolutionary routes cell‐by‐cell was far from applicable. Now, with the help of spatial omics, tracing cancer evolution at different space coordinates and cellular units is now possible.…”

Carbon Dot Therapeutic Platforms: Administration, Distribution, Metabolism, Excretion, Toxicity, and Therapeutic Potential

“…[131] The core of the tumorous mass is the true intended target for targeted cancer therapy as this is where the most aggressive sub-clonal growth stems from resulting in increased proliferation, somatic copy number, and Fuhrman grade. [132] To reach the core, additional strategies may be employed to facilitate movement into this region including the functionalization of CDs with "enhanced permeability and retention" agents or triggering CDs with external radiation stimuli (i.e., ultrasound, radiotherapy, photodynamic, or hyperthermia) to physically enhance access (Figure 4). [24]…”